Nuclear factor κB (NF-κB) pathway as a therapeutic target in rheumatoid arthritis

Journal of Korean Medical Science

Volumn 14, Issue 3, 1999, Pages 231-238

  Jue, Dae Myung ^a   Jeon, Kye Im ^a   Jeong, Jae Yeon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Anti inflammatory agents; Antirheumatic agents; Arthritis, rheumatoid; Interleukin 1; Monokines; NF B; Tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033144367     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.1999.14.3.231     Document Type: Review

References (79)

1. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39: 616-22.
2. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
3. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 1997; 40: 5-18.
4. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990; 33: 768-73.
5. Palmer DG. The anatomy of the rheumatoid lesion. Brit Med Bull 1995; 51: 286-95.
6. Duff GW. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 1994; 100: 9-19.
7. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-60.
8. van de Loo AA, Arntz OJ, Bakker AC, van Lent PL, Jacobs MJ, van den Berg WB. Role of interleukin 1 in antigen-induced exacerbations of marine arthritis. Am J Pathol 1995; 146: 239-49.
9. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND. The effect of an interleukin-1 receptor antagonist protein on type 11 collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 1305-14.
10. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992; 89: 7375-9.
11. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-4.
12. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.
13. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602-7.
14. Brennan FM, Maini RN, Feldmann M. TNFα-a pivotal role in rheumatoid arthritis? Brit J Rheumatol 1992; 31: 293-8.
15. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
16. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681-90.
17. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
18. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
19. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
20. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
21. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995; 25: 1794-7.
22. Vey E, Burger D, Dayer JM. Expression and cleavage of tumor necrosis factor-α and tumor necrosis factor receptor by human monocytic cell lines upon direct contact with stimulated T cells. Eur J Immunol 1996; 26: 2404-9.
23. Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature 1989; 338: 225-8.
24. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, MeLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-46.
25. Yao J, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-κB transcription factors. J Biol Chem 1997; 272: 17795-801.
26. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-κB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998; 273: 21178-86.
27. Zagariya A, Mungre S, Lovis R, Birrer M, Ness S, Thimmapaya B, Pope R. Tumor necrosis factor α gene regulation: enhancement of C/EBP-induced activation by c-Jun. Mol Cell Biol 1998; 18: 2815-24.
28. McCaffrey PG, Goldfeld AE, Rao A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-α gene transcription. J Biol Chem 1994; 269: 30445-50.
29. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 1990; 171: 35-47.
30. Ziegler-Heitbrock HW, Sternsdorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Bauerle P, Strobel M. Pyrrolidine dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes. J Immunol 1993; 151: 6986-93.
31. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, Brennan F, Feldmann M. Efficient adenoviral infection with IκBa reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci USA 1998; 95: 8211-5.
32. May MJ, Ghosh S. Signal transduction through NF-κB. Immunol Today 1998; 19: 80-8.
33. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996; 84: 853-62.
34. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin MA. Cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997; 388: 548-54.
35. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation Science 1997; 278: 860-6.
36. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. Cell 1997; 90: 373-83.
37. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 1997; 278: 866-9.
38. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M.. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997; 91: 243-52.
39. Lee FS, Peters RT, Dang LC, Maniatis T. MEKK1 activates both IκB kinase α and IκB kinase β. Proc. Natl. Acad. Sci. USA 1998; 95: 9319-24.
40. Zandi E, Chen Y, Karin M. Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 1998; 281: 1360-3.
41. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999; 284: 316-20.
42. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N, Akira S. Limb and skin abnormalities in mice lacking IKKα Science 1999; 284: 313-6.
43. Li Q, Van Antwerp D, Mercurio F, Lee K-F, Verma IM. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 1999; 284: 321-5.
44. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 1999; 284: 309-13.
45. Cohen L, Henzel WJ, Baeuerle PA. IKAP is a scaffold protein of the IκB kinase complex. Nature 1998; 395: 292-6.
46. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 1998; 395: 297-300.
47. Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T. Apoptosis in rheumatoid arthritis. A novel pathway in the regulation of synovial tissue. Arthritis Rheum 1998; 41: 1-9.
48. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 274: 782-4.
49. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-7.
50. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787-9.
51. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 1996; 87: 565-76.
52. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-3.
53. Wu MX, Ao Z, Prasad KVS, Wu R, Schlossman SF. IEX-IL, an apoptosis inhibitor involved in NF-κB-mediated cell surmal. Science 1998; 281: 998-1001.
54. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS, Makarov SS. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95: 13859-64.
55. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5.
56. Weissmann G. Aspirin. Sci Am 1991; 264: 58-64.
57. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265: 956-9.
58. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998; 396: 77-80.
59. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752-6.
60. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 1995; 15: 943-53.
61. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286-90.
62. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
63. Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? Brit Med J Clin Res 1985; 290: 1535-8.
64. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor κB. J Clin Invest 1998; 101: 1163-74.
65. Research Subcommittee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: report of a multi-centre controlled trial. Ann Rheum Dis 1960; 19: 95-119.
66. Grahame R, Billings R, Laurence M, Marks V, Wood PJ. Tissue gold levels after chrysotherapy. Ann Rheum Dis 1974; 33: 536-9.
67. Vernon-Roberts B, Dore JL, Jessop JD, Henderson, WJ. Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients. Ann Rheum Dis 1976; 35: 477-86.
68. Yanni G, Nabil M, Farahat MR, Poston RN, Panayi GS. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis 1994; 53: 315-22:
69. Bondeson J, Sundler R. Auranofin inhibits the induction of interleukin Iβ and tumor necrosis factor α mRNA in macrophages. Biochem Pharmacol 1995; 50: 1753-9.
70. Jeon K-I, Jeong J-Y, Jue D-M. Unpublished observation
71. Yang JP, Merin JP, Nakano T, Kato T, Kitade Y, Okamoto T. Inhibition of the DNA-binding activity of NF-κB by gold compounds in vitro. FEBS Lett 1995; 361: 89-96.
72. Ertel W, Morrison MH, Ayala A, Chaudry IH. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 1991; 78: 1781-8.
73. Picot S, Peyron F, Donadille A, Vuillez J-P, Barbe G, Ambroise-Thomas P. Chloroquine-inditced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993; 80: 127-33.
74. Jeong J-Y, Jue D-M. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997; 158: 4901-7.
75. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5: 298-304.
76. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
77. Cronstein BN, Naime D, Firestein G. The anti-inflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 1995; 38: 1040-5.
78. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 4159-68.
79. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol 1996; 156: 3435-42.